Armillaridin, a Honey Medicinal Mushroom, Armillaria mellea (Higher Basidiomycetes) Component, Inhibits Differentiation and Activation of Human Macrophages.
Armillaridin (AM) is an aromatic ester compound isolated from honey medicinal mushroom, Armillaria mellea, which has anti-cancer potential. This study was designed to examine the effects of AM on differentiation and activation macrophages, the major ontogeny of innate immunity. Macrophages were derived from CD14+ monocytes which were sorted from human peripheral blood mononuclear cells. Cell viability was assessed by trypan blue exclusion test. Cells were stained with Liu's dye for observation of morphology. Expression of surface antigens was examined by flow cytometric analysis. Phagocytosis and generation of reactive oxygen species (ROS), as functional assays, were evaluated by counting engulfed yeasts and DCFH-DA reaction. The viability of macrophages was not significantly reduced by AM. AM at nontoxic concentrations markedly increased cytoplasmic vacuoles. The expression of surface CD14, CD16, CD36, and HLA-DR was suppressed. The phagocytosis function, but not ROS production, of macrophages was inhibited by AM. Armillaridin could inhibit the differentiation and activation of human macrophages. It may have potential to be developed as a biological response modifier for inflammatory diseases.
Department of Surgery, Mackay Memorial Hospital, Mackay Junior College of Medicine, Nursing and Management, Department of Graduate Institute of Cancer Biology and Drug Medicine Taipei Medical University, Department of Medicine Mackay Medical College.
Tsang-Pai
TP
Liu
Department of Biotechnology, Hungkuang University, Taichung, Taiwan.
Chien-Chih
CC
Chen
Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan.
Pei-Yu
PY
Shiao
Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan.
Hui-Ru
HR
Shieh
Department and Graduate School of Physical Education, National Taiwan Sport University, Taichung, Taiwan.
Yu-Yawn
YY
Chen
Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan; Department of Radiation Oncology, Mackay Memorial Hospital, Taipei, Taiwan; Graduate Institute of Pharmacology, Taipei Medical University, Taipei, Taiwan.
Yu-Jen
YJ
Chen
D000941:Antigens / Q000378:metabolism; D055392:Armillaria / Q000737:chemistry*; D001688:Biological Products / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D005452:Fluoresceins / Q000378:metabolism; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects*; D007155:Immunologic Factors / Q000494:pharmacology; D008262:Macrophage Activation / Q000187:drug effects*; D008264:Macrophages / Q000187:drug effects* / Q000378:metabolism; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D010587:Phagocytosis / Q000187:drug effects; D017382:Reactive Oxygen Species / Q000378:metabolism; D012717:Sesquiterpenes / Q000494:pharmacology*; D014617:Vacuoles; D015003:Yeasts
D000941:Antigens; D001688:Biological Products; D005452:Fluoresceins; D007155:Immunologic Factors; D017382:Reactive Oxygen Species; D012717:Sesquiterpenes; C029569:diacetyldichlorofluorescein; C043543:armillaridin